This important result supports the hypothesis that the pleiotropic hormone leptin in COPD disease is a pro-inflammatory cytokine per se regardless of the amount of the adipose tissue, first organ of leptin production: this leads to the concept that leptin may be considered for clinical practice as a circulating new biomarker for early diagnosis and better management of COPD disease. This evidence concerns the gene LEP and chronic obstructive pulmonary disease.